DDIT3 and mature T-cell and NK-cell non-Hodgkin lymphoma: However, when combined with pralatrexate or CHOP, the adverse reactions were not only reduced but also significantly alleviated in PTCL patients, with the ORR reaching 70–80%, which was also consistent with the findings of other reported literature [49] (shown as Table 3).